SG Americas Securities
APLS

SG Americas Securities’s Apellis Pharmaceuticals APLS Stock Holding History

SG Americas Securities’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,000
Closed -$284K – 3459
2024
Q4 		$284K Hold
35,000
– – ﹤0.01% 1841
2024
Q3 		$357K Hold
35,000
– – ﹤0.01% 1983
2024
Q2 		$280K Hold
35,000
– – ﹤0.01% 1998
2024
Q1 		$108K Buy
+35,000
New +$2.23M ﹤0.01% 2494
2023
Q4 		– Sell
-98,400
Closed -$536K – 3091
2023
Q3 		$536K Buy
+98,400
New +$4.32M 0.01% 1711

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SG Americas Securities's APLS Position: Q2 2026 in Review

SG Americas Securities sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 29,601 shares — an estimated $1.19M sold.

SG Americas Securities first reported a position in APLS in Q1 2019 and held it in 28 quarters. The position peaked at $14.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • SG Americas Securities reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 29,601 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
  • SG Americas Securities first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 28 quarters.
  • SG Americas Securities's Apellis Pharmaceuticals position peaked at $14.2M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.